Earnings GrowthMDXH turned in a strong Q1, driving +22% Y/Y organic revenue growth on the back of +41% Y/Y volume growth from its tissue-based tests and +9% Y/Y volume growth from its liquid-based test portfolio.
Profitability MilestoneMDxHealth is on track to achieve its AEBITDA positivity milestone, which is critical to de-risking the model further.
ValuationWith shares trading at under 1 times NTM revenue, the company’s growth outlook and commercial infrastructure are significantly undervalued, suggesting room for multiple expansion.